Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery

Best Practice and Research: Clinical Haematology

Volumn 26, Issue 2, 2013, Pages 171-182

  Quinlan, Daniel J ^a   Eriksson, Bengt I ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

anticoagulant; apixaban; dabigatran; deep vein thrombosis; pulmonary embolism; rivaroxaban; thromboprophylaxis; total hip arthroplasty; total knee arthroplasty

Indexed keywords

APIXABAN; DABIGATRAN; EDOXABAN; ENOXAPARIN; RIVAROXABAN;

BLEEDING; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MAXIMUM PLASMA CONCENTRATION; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VENOUS THROMBOEMBOLISM;

EID: 84882263590     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2013.07.003     Document Type: Review

References (44)

1. R. Guijarro, J. Montes, and C. San Román Venous thromboembolism and bleeding after total knee and hip arthroplasty. Findings from the Spanish National Discharge Database Thromb Haemost 105 2011 610 615
2. Y. Falck-Ytter, C.W. Francis, and N.A. Johanson Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 141 2012 e278S e325S
3. J.M. Januel, G. Chen, and C. Ruffieux Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review JAMA 307 2012 294 303
4. American Academy of Orthopaedic Surgeons. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. Evidence-based guideline and evidence report. http://www.aaos.org/ research/guidelines/VTE/VTE-full-guideline.pdf.
5. R.J. Friedman, A.S. Gallus, and F.D. Cushner Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty Curr Med Res Opin 24 2008 87 97
6. O.E. Dahl, D.J. Quinlan, and D. Bergqvist A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty J Thromb Haemost 8 2010 1966 1975
7. J. Berger, J.W. Eikelboom, and D.J. Quinlan Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an ad hoc working group meeting J Thromb Haemost 11 2013 778 782
8. B.I. Eriksson, D.J. Quinlan, and J.I. Weitz Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development Clin Pharmacokinet 48 2009 1 22
9. J. Stangier, K. Rathgen, and H. Stähle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
10. K. Ogata, J. Mendell-Harary, and M. Tachibana Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers J Clin Pharmacol 50 2010 743 753
11. A. Gómez-Outes, A.I. Terleira-Fernández, and M.L. Suárez-Gea Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons BMJ 344 2012 e3675
12. B.I. Eriksson, O.E. Dahl, and N. Rosencher Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956
13. B.I. Eriksson, O.E. Dahl, and M.H. Huo Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial Thromb Haemost 105 2011 721 729
14. B.I. Eriksson, O.E. Dahl, and N. Rosencher Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185
15. RE-MOBILIZE Writing Committee, J.S. Ginsberg, and B.L. Davidson Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
16. B.I. Eriksson, J.J. Smith, and J. Caprini Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials Thromb Res 130 2012 396 402
17. N. Rosencher, H. Noack, and M. Feuring Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials Thromb J 10 2012 9
18. B.I. Eriksson, O.E. Dahl, and M. Feuring Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis Thromb Res 130 2012 818 820
19. B.I. Eriksson, O.E. Dahl, and N. Rosencher Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis Thromb Res 130 2012 871 876
20. B.I. Eriksson, D.J. Quinlan, and J.W. Eikelboom Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism Annu Rev Med 62 2011 41 57
21. B.I. Eriksson, L.C. Borris, and R.J. Friedman Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775
22. A.K. Kakkar, B. Brenner, and O.E. Dahl Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
23. M.R. Lassen, W. Ageno, and L.C. Borris Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786
24. A.G. Turpie, M.R. Lassen, and B.L. Davidson Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
25. A.G. Turpie, M.R. Lassen, and B.I. Eriksson Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
26. N. Rosencher, J.V. Llau, and W. Mueck Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin) Acta Anaesthesiol Scand 57 2013 565 572
27. M.R. Lassen, G.E. Raskob, and A. Gallus Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
28. M.R. Lassen, G.E. Raskob, and A. Gallus Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
29. M.R. Lassen, A. Gallus, and G.E. Raskob Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
30. G.F. Pineo, A.S. Gallus, and G.E. Raskob Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups J Thromb Haemost 11 2013 444 451
31. T. Fuji, C.-J. Wang, and S. Fujita Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial (abstract) Pathophysiol Haemost Thromb 37 2010 A20
32. T. Fuji, S. Fujita, and S. Tachibana Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial (abstract) Blood 116 2010 19
33. S. Fujita, T. Fuji, and S. Tachibana Safety and efficacy of edoxaban in patients undergoing hip fracture surgery (abstract) Pathophysiol Haemost Thromb 37 2010 A95
34. Pradaxa Summary of product characteristics, version 7 Feb 2013 Accessed at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000829/WC500041059.pdf
35. Xarelto Summary of product characteristics, version 5 Feb 2013 Accessed at: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000944/WC500057108.pdf
36. Xarelto US prescribing information, version March 2013 Available from: www.xareltohcp.com/prescribing-information.pdf
37. Eliquis Summary of product characteristics, version 20 Dec 2012 Accessed at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/002148/WC500107728.pdf
38. R.J. Friedman, A. Kurth, and A. Clemens Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding Thromb Haemost 108 2012 183 190
39. B.I. Eriksson, N. Rosencher, and R.J. Friedman Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty Thromb Res 130 2012 147 151
40. O.E. Dahl, M. Ogren, and G. Agnelli Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplasty Pathophysiol Haemost Thromb 35 2006 428 434
41. W. Gogarten, E. Vandermeulen, and A.H. van Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology Eur J Anaesthesiol 27 2010 999 1015
42. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
43. J.I. Weitz, D.J. Quinlan, and J.W. Eikelboom Periprocedural management and approach to bleeding in patients taking dabigatran Circulation 126 2012 2428 2432
44. J.W. Eikelboom, and J.I. Weitz New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty BMJ 342 2011 c7270